Pacira BioSciences (PCRX) FCF Margin (2010 - 2026)

Pacira BioSciences' FCF Margin history runs 17 years deep, the most recent figure standing at 13.71% for Q1 2026.

• In Q1 2026, FCF Margin fell 222.0% year-over-year to 13.71%; the TTM figure through Mar 2026 stood at 20.13% (down 255.0% YoY), while the FY2025 annual figure was 20.72%, down 478.0% from the prior year.
• FCF Margin was 13.71% for Q1 2026 at Pacira BioSciences, down from 29.12% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 32.29% in Q3 2023 to a low of 7.62% in Q4 2022.
• Historically, FCF Margin has averaged 18.9% across 5 years, with a median of 18.7% in 2023.
• The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 4097 bps in 2022, then jumped 2632 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 7.62% in 2022, then surged by 345 bps to 18.7% in 2023, then slumped by 35 bps to 12.24% in 2024, then jumped by 138 bps to 29.12% in 2025, then sank by 53 bps to 13.71% in 2026.
• The last three FCF Margin figures came in at 13.71% (Q1 2026), 29.12% (Q4 2025), and 31.73% (Q3 2025), per Business Quant data.